Related Experiment Video
Updated: Aug 3, 2025
07:45
An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
Published on: October 21, 2014
8.0K
Rapamycin Alleviates Protein Aggregates, Reduces Neuroinflammation, and Rescues Demyelination in Globoid Cell
Dar-Shong Lin1,2, Yu-Wen Huang3, Tsung-Han Lee3
1Department of Pediatrics, MacKay Memorial Hospital, Taipei 10449, Taiwan.
Cells
|April 13, 2023
Summary
Rapamycin treatment effectively reduced toxic protein aggregates and neuroinflammation in a mouse model of globoid cell leukodystrophy (GLD). This therapeutic strategy improved brain pathology and extended lifespan, offering hope for treating GLD and similar neurodegenerative diseases.
Area of Science:
- Neuroscience
- Biochemistry
- Genetics
Background:
- Globoid cell leukodystrophy (GLD) is a lysosomal storage disease causing demyelination.
- Psychosine accumulation impairs cellular waste disposal systems, including autophagy and the ubiquitin-proteasome system, contributing to GLD pathogenesis.
Purpose of the Study:
- To investigate the therapeutic potential of rapamycin, an mTOR inhibitor, in twitcher mice, a model for infantile GLD.
- To assess rapamycin's effects on biochemical, histochemical, and clinical aspects of GLD.
Main Methods:
- Rapamycin was administered to twitcher mice.
- Brain tissue was analyzed for mTOR signaling, ubiquitinated protein accumulation, and glial cell reactivity.
- Histochemical analysis assessed myelination and neurite density.
- Clinical outcomes, including lifespan, were monitored.
Main Results:
- Rapamycin inhibited mTOR signaling in the brains of treated mice.
- Accumulation of insoluble ubiquitinated proteins and ubiquitin aggregates was significantly reduced.
- Reactivity of astrocytes and microglia, along with globoid cells, was attenuated.
- Cortical myelination, neurite density, and network complexity were improved.
- Lifespan of treated twitcher mice was prolonged.
Conclusions:
- Rapamycin demonstrates therapeutic efficacy in the twitcher mouse model of GLD.
- Enhancing the degradation of intracellular aggregates is a promising strategy for treating GLD and related leukodystrophies.
- Rapamycin can modulate neuroinflammation, demyelination, and disease progression in GLD.
